[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 66 of about 66
1. Birgersdotter A, Baumforth KR, Porwit A, Sjöberg J, Wei W, Björkholm M, Murray PG, Ernberg I: Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma. Br J Cancer; 2009 Oct 20;101(8):1393-401
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma.
  • BACKGROUND: Classical Hodgkin's lymphoma (cHL), although a malignant disease, has many features in common with an inflammatory condition.
  • The aim of this study was to establish the molecular characteristics of the two most common cHL subtypes, nodular sclerosis (NS) and mixed cellularity (MC), based on molecular profiling and immunohistochemistry, with special reference to the inflammatory microenvironment.
  • METHODS: We analysed 44 gene expression profiles of cHL whole tumour tissues, 25 cases of NS and 19 cases of MC, using Affymetrix chip technology and immunohistochemistry.
  • Fifty-three genes had a higher expression in the MC subtype, including several inflammation-related genes, such as C1Qalpha, C1Qbeta and CXCL9.
  • In MC tissues, the C1Q subunits were mainly expressed by infiltrating macrophages.
  • [MeSH-major] Gene Expression Profiling. Hodgkin Disease / classification. Hodgkin Disease / pathology. Inflammation / pathology. Wound Healing
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers. Extracellular Matrix / metabolism. Female. Fibrosis. Humans. Immunohistochemistry. Male. Middle Aged


2. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood; 2006 Dec 1;108(12):3786-91
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS.
  • In persons with HIV/AIDS (PWHAs), Hodgkin lymphoma (HL) risk is increased.
  • For each HL subtype, incidence decreased with declining CD4 counts, but nodular sclerosing decreased more precipitously than mixed cellularity, thereby increasing the proportion of mixed cellularity HL seen in PWAs.
  • With more severe immunosuppression, nodular sclerosing HL becomes infrequent, explaining the higher proportion of mixed cellularity HL found in PWAs.


3. Cabrera ME, García H, Lois V, León A, Peña K, Rossle A, Cerda B, Rojas H, Meneses P, Merino C, Aspillaga A, Vittini de C, Oliva J, Hales C, Rosas J, Programa Nacional de Cáncer del Adulto, Ministerio de Salud: [Hodgkin lymphoma in Chile: experience of the national adult cancer program]. Rev Med Chil; 2007 Mar;135(3):341-50
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin lymphoma in Chile: experience of the national adult cancer program].
  • BACKGROUND: Hodgkin lymphoma is a highly curable disease.
  • AIM: To evaluate the clinical characteristics and the treatment results of Hodgkin lymphoma patients of the National Cancer Program in Chile.
  • PATIENTS AND METHODS: Prospective assessment of 682 patients treated in 18 adult cancer centers.
  • Nodular sclerosis and mixed cellularity were equally expressed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. National Health Programs
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bleomycin / administration & dosage. Chi-Square Distribution. Chile. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prospective Studies. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505580.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Chile
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; ABVD protocol; CMOPP protocol; NOVP protocol
  • [Investigator] Hales C; López H; Zambrano V; Blanchard N; Vacarezza R; Merino C; Toro I; Meneses P; Rojas B; Aspillaga A; Fahrenkrog A; Rossle A; Bancalari G; Fernández A; García C; Schorwer M; Pérez C; Oliva J; Vittini de R C; Yáñez E; Peña A; Rodríguez C; León A; Pilleux L; Calderón S; Salas P; Lesina B; Zapata C; Cardemil B; Zumelzu N; Silva M; Rosas J; González ML; Liberón B; Cerda B; Klivadenko W; Sola A; Cao C; Peña K; Puente L; Bronfman L; Torrens M; Gutiérrez J; Cabrera ME; Undurraga MS; Gray AM; Puga B; Guerra C; Vacarezza R; Etcheverrry R; Ducach G; García H; Riquelme AM; Corvalán H; Lois V; Con I; Muñoz L; Bustos MI; Castro JL; Liendo F; Osorio G; Araos D; Anguita T; Rojas H; Suárez D
  •  go-up   go-down


Advertisement
4. Mani H, Jaffe ES: Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma; 2009 Jun;9(3):206-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma: an update on its biology with new insights into classification.
  • In the past few years, there has been a greater understanding of the spectrum and biology of Hodgkin lymphoma (HL).
  • In standard texts, HL is classified as 2 distinct entities, namely nodular lymphocyte-predominant HL and classical HL (CHL).
  • However, recent evidence suggests that CHL is not a single disease.
  • Although the mixed cellularity and lymphocyte-depleted subtypes might be part of a biologic continuum, the nodular sclerosis subtype has a distinct epidemiology, clinical presentation, and histology.
  • Nodular sclerosis HL might also be related to primary mediastinal B-cell lymphoma and mediastinal gray-zone lymphomas.
  • [MeSH-major] Hodgkin Disease / classification. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Apoptosis. Cytokines / metabolism. Female. Genetic Predisposition to Disease. HIV Infections / metabolism. Herpesvirus 4, Human / metabolism. Humans. Immunophenotyping. Lymphocytes / metabolism. Lymphoma, B-Cell / metabolism. Male. Social Class

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 1;94(9):3108-13 [10556196.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):387-94 [10637283.001]
  • [Cites] J Exp Med. 2004 Apr 19;199(8):1041-52 [15078899.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Natl Cancer Inst. 2004 May 19;96(10):780-4 [15150306.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]
  • [Cites] Blood. 1999 Jul 15;94(2):411-6 [10397707.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3122-7 [10506608.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:184-202 [15561683.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Mar;37(3):511-7 [15618006.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):395-402 [10637284.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1443-50 [10666223.001]
  • [Cites] Blood. 2000 May 15;95(10):3020-4 [10807764.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1889-99 [10961891.001]
  • [Cites] Isr Med Assoc J. 2000 Jul;2(7):501-3 [10979320.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):262-9 [11091850.001]
  • [Cites] Blood. 2001 Jan 15;97(2):496-501 [11154228.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):297-306 [11224599.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):219-28 [11266530.001]
  • [Cites] Hematol Oncol. 2001 Mar;19(1):1-17 [11276042.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2080-4 [11280769.001]
  • [Cites] Blood. 2001 May 1;97(9):2798-807 [11313274.001]
  • [Cites] Histopathology. 2001 Apr;38(4):368-75 [11318902.001]
  • [Cites] Blood. 2001 May 15;97(10):3191-6 [11342448.001]
  • [Cites] Blood. 2001 Jul 1;98(1):194-200 [11418480.001]
  • [Cites] Blood. 2001 Aug 1;98(3):762-70 [11468177.001]
  • [Cites] Mol Med. 2001 May;7(5):285-92 [11474574.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1807-14 [11696441.001]
  • [Cites] Blood. 2002 Jan 1;99(1):258-67 [11756180.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] Blood. 2002 Jan 15;99(2):618-26 [11781246.001]
  • [Cites] Blood. 2002 Jan 15;99(2):690-3 [11781255.001]
  • [Cites] Leuk Res. 2002 Mar;26(3):261-9 [11792415.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):585-96 [11839579.001]
  • [Cites] Curr Opin Immunol. 2002 Apr;14(2):216-23 [11869895.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3753-8 [12881319.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):767-77 [14608905.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1141-7 [14614054.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1513-22 [14657710.001]
  • [Cites] Eur J Haematol. 2004 Jan;72(1):1-9 [14962256.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):103-13 [16949642.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):875-9 [17131320.001]
  • [Cites] Adv Anat Pathol. 2007 May;14(3):189-94 [17452815.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2700-7 [17119127.001]
  • [Cites] Hematol Oncol. 2004 Mar;22(1):11-26 [15152367.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):609-11 [15160926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1236-43 [15247136.001]
  • [Cites] Acta Haematol. 2004;112(3):129-35 [15345894.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1375-84 [15359636.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1551-7 [15370206.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1063-83 [5947336.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1189-201 [5329907.001]
  • [Cites] Bull Hist Med. 1969 Mar-Apr;43(2):138-75 [4890530.001]
  • [Cites] Bull N Y Acad Med. 1970 Jan;46(1):67-9 [4903331.001]
  • [Cites] Int J Cancer. 1971 Sep 15;8(2):192-201 [5133848.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):248-50 [831107.001]
  • [Cites] Am J Pathol. 1977 Apr;87(1):19-32 [322504.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1979;31(3):211-25 [43015.001]
  • [Cites] Ann Intern Med. 1980 May;92(5):587-95 [6892984.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] Immunol Rev. 1983;70:167-92 [6403456.001]
  • [Cites] Br J Cancer. 1983 May;47(5):707-12 [6849804.001]
  • [Cites] Am J Clin Pathol. 1984 Dec;82(6):666-73 [6391148.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):599-606 [3041849.001]
  • [Cites] Cancer. 1989 Mar 15;63(6):1150-3 [2917317.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1686-93 [2790683.001]
  • [Cites] J Natl Cancer Inst. 1990 May 16;82(10):855-8 [2185367.001]
  • [Cites] N Engl J Med. 1992 Apr 23;326(17):1115-22 [1532439.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):252-8 [1599017.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1308-16 [9694719.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S21-4 [9926233.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S31-8 [9926235.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] N Engl J Med. 1999 Apr 22;340(16):1239-47 [10210707.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3964-72 [10339506.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1685-91 [10362793.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):90-6 [15389259.001]
  • [Cites] Am J Pathol. 2005 Jan;166(1):127-34 [15632006.001]
  • [Cites] J Pathol. 2005 Apr;205(5):541-7 [15732141.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 15;158(2):167-71 [15796964.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):199-205 [15813847.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4048-56 [15961758.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] Histopathology. 2005 Jul;47(1):101-10 [15982329.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):26-33 [16007865.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5052-60 [15955904.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):747-55 [16084943.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] Ann Hematol. 2005 Oct;84(10):661-6 [15875183.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1411-21 [16224207.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1581-91 [16236613.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1542-9 [16056244.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:231-8 [16304386.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2360-2 [16224482.001]
  • [Cites] Cell Signal. 2006 Apr;18(4):449-55 [15967637.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):92-100 [16360421.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):7 [16391364.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):495-501 [16396774.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):66-76 [16399588.001]
  • [Cites] J Pathol. 2006 Feb;208(3):423-30 [16353293.001]
  • [Cites] Expert Opin Ther Targets. 2006 Feb;10(1):27-35 [16441226.001]
  • [Cites] Adv Cancer Res. 2002;84:277-312 [11883530.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):567-72 [11920617.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2493-503 [11971184.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:11-8 [12078890.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:44-51 [12078902.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:75-8 [12078907.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3095-102 [12082542.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4908-20 [12118370.001]
  • [Cites] J Pathol. 2002 Nov;198(3):310-6 [12375263.001]
  • [Cites] Immunity. 2002 Oct;17(4):473-85 [12387741.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3151-8 [12483718.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):16-26 [12502924.001]
  • [Cites] Blood. 2003 Jan 15;101(2):706-10 [12393409.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1505-12 [12393731.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1813-8 [12685837.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Int J Hematol. 2003 May;77(4):330-5 [12774919.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):843-58 [12852658.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):706-12 [12866030.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):126-36 [12939740.001]
  • [Cites] Leuk Lymphoma. 2003 Aug;44(8):1325-31 [12952225.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):206-13 [12966346.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1346-56 [14508396.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2214-9 [14523479.001]
  • [Cites] J Pathol. 2003 Nov;201(3):413-20 [14595753.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3434-40 [16868249.001]
  • [Cites] Pathobiology. 2006;73(3):107-25 [17085956.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1326-9 [17438085.001]
  • [Cites] J Clin Pathol. 2007 Oct;60(10):1092-7 [17158640.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1252-7 [18594468.001]
  • [Cites] Blood. 2005 May 15;105(10):4051-9 [15677564.001]
  • [Cites] Arch Pathol Lab Med. 1992 Sep;116(9):969-72 [1524465.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):859-67 [1384376.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):885-95 [1415907.001]
  • [Cites] Semin Diagn Pathol. 1992 Nov;9(4):297-303 [1480852.001]
  • [Cites] Am J Surg Pathol. 1993 Feb;17(2):123-32 [8422110.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1595-602 [8123850.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):526-30 [8172327.001]
  • [Cites] Br J Haematol. 1994 Mar;86(3):513-23 [7519036.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] Ann Oncol. 1995 May;6(5):477-82 [7545429.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1294-9 [7573692.001]
  • [Cites] Int J Cancer. 1996 Apr 10;66(2):179-83 [8603808.001]
  • [Cites] Blood. 1996 May 1;87(9):3844-51 [8611711.001]
  • [Cites] Leukemia. 1996 May;10(5):829-35 [8656679.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1279-87 [8827036.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):538-42 [8849727.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Semin Cancer Biol. 1996 Aug;7(4):217-26 [8946606.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):543-62 [9033270.001]
  • [Cites] Immunol Today. 1997 Apr;18(4):156-63 [9136451.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 2:79-81 [9209647.001]
  • [Cites] Pathology. 1997 Aug;29(3):294-9 [9271021.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):229-35 [9520936.001]
  • [Cites] Blood. 1998 Aug 1;92(3):790-4 [9680346.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1272-6 [9697883.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2493-500 [16304050.001]
  • [Cites] Immunol Lett. 2006 Apr 15;104(1-2):83-8 [16386314.001]
  • [Cites] Indian Pediatr. 2006 Feb;43(2):141-7 [16528110.001]
  • [Cites] Trends Immunol. 2006 May;27(5):203-5 [16563865.001]
  • [Cites] Ann Hematol. 2006 Jul;85(7):463-8 [16534596.001]
  • [Cites] Am J Clin Pathol. 2006 May;125(5):776-82 [16707382.001]
  • [Cites] Yale J Biol Med. 2005 Jul;78(4):203-10 [16720015.001]
  • [Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5716-22 [16740709.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):1010-8 [16648862.001]
  • [Cites] Int J Hematol. 2006 Jun;83(5):391-7 [16787868.001]
  • [Cites] Int J Hematol. 2006 Jun;83(5):398-403 [16787869.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):469-78 [16894295.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):352-60 [16770772.001]
  • [Cites] Acta Haematol. 2006;116(2):101-7 [16914904.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2037-49 [16919769.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):315-9 [16896892.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1518-22 [16966262.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Sep;28(9):552-8 [17006259.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4626-33 [16954517.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1844-51 [16983704.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1863-71 [17064999.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1932-40 [17065008.001]
  • [Cites] Tumour Biol. 2006;27(6):329-33 [17033203.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2115-27 [17071485.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10332-8 [17079453.001]
  • (PMID = 19525189.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC011070-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 204
  • [Other-IDs] NLM/ NIHMS161993; NLM/ PMC2806063
  •  go-up   go-down


5. Iyengar P, Mazloom A, Shihadeh F, Berjawi G, Dabaja B: Hodgkin lymphoma involving extranodal and nodal head and neck sites: characteristics and outcomes. Cancer; 2010 Aug 15;116(16):3825-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma involving extranodal and nodal head and neck sites: characteristics and outcomes.
  • BACKGROUND: Most Hodgkin lymphoma (HL) patients present with disease in nodal regions.
  • However, in a small subset, disease develops in unique anatomic sites such as the head and neck area.
  • Specifically, 10 of 34 patients had disease in the tonsils, 9 in the nasopharynx, 8 in the thyroid, 3 in the parotid, 2 in the adenoids, and 1 each in Waldeyer's ring and nasal antrum.
  • Median age at diagnosis was 31.5 years, average age at diagnosis was 38 years, and 22 of 34 were male; 23 had stage I or II disease.
  • Pathologically, 14 of 34 had the nodular sclerosis subtype, whereas 15 had mixed cellularity.
  • Twenty-nine of 34 had nodal neck disease at presentation.
  • At last follow-up, 85% were disease-free.
  • CONCLUSIONS: HL of the head and neck is primarily diagnosed as early stage disease of men and of young to middle-aged individuals.
  • The extent to which nodal disease is present in the neck does not alter outcomes when combined modality therapy is offered.
  • Despite the unique anatomic location of these lesions, standard HL protocols work effectively to promote disease-free survival.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • (PMID = 20564093.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Díez-Martín JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, Conde E, Rosselet A, Gabriel I, Varela R, Allione B, Cwynarski K, Genet P, Espigado I, Biron P, Schmitz N, Hunter AE, Ferrant A, Guillerm G, Hentrich M, Jurado M, Fernández P, Serrano D, Rossi G, Sureda A, European Group for Blood and Marrow Transplantation Lymphoma Working Party: Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood; 2009 Jun 4;113(23):6011-4
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation.
  • Autologous stem cell transplantation (ASCT) has been successfully used in HIV-related lymphoma (HIV-Ly) patients on highly active antiretroviral therapy.
  • We report the first comparative analysis between HIV-Ly and a matched cohort of HIV(-) lymphoma patients.
  • This retrospective European Group for Blood and Marrow Transplantation study included 53 patients (66% non-Hodgkin and 34% Hodgkin lymphoma) within each cohort.
  • Both groups were comparable except for the higher proportion of males, mixed-cellularity Hodgkin lymphoma and patients receiving granulocyte colony-stimulating factor before engraftment and a smaller proportion receiving total body irradiation-based conditioning within the HIV-Ly cohort.
  • Thus, within the highly active antiretroviral therapy era, HIV patients should be considered for ASCT according to the same criteria adopted for HIV(-) lymphoma patients.
  • [MeSH-major] HIV Infections / surgery. Hodgkin Disease / surgery. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Survival Rate. Transplantation, Autologous


7. Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balagué O, Gel B, Abrisqueta P, Lopez-Guillermo A, Artells R, Montserrat E, Monzo M: MicroRNA expression profiling in classic Hodgkin lymphoma. Blood; 2008 Mar 1;111(5):2825-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression profiling in classic Hodgkin lymphoma.
  • We analyzed miRNA expression in classic Hodgkin lymphoma (cHL) and the influence of Epstein-Barr virus (EBV) infection on the miRNA expression profiles.
  • Hierarchic clustering revealed 3 well-defined groups: nodular sclerosis cHL, mixed cellularity cHL, and RLNs.
  • A distinctive signature of 25 miRNAs differentiated cHL from RLNs, and 36 miRNAs were differentially expressed in the nodular sclerosis and mixed cellularity subtypes.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Hodgkin Disease / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Herpesvirus 4, Human / physiology. Humans. In Situ Hybridization. Lymph Nodes / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089852.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


8. Müller J, Molnár Z, Illés A, Csóka M, Jakab Z, Deák B, Schneider T, Várady E, Rosta A, Simon Z, Keresztes K, Gergely L, Kovács G: [Hodgkin's lymphoma in adolescents: where to treat it--in an adult or pediatric institution?]. Orv Hetil; 2008 Nov 23;149(47):2221-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin's lymphoma in adolescents: where to treat it--in an adult or pediatric institution?].
  • [Transliterated title] Hodgkin-lymphoma adolescens korban. Hol érdemes kezelni: felnôtt- vagy gyermekintézményben?
  • Adolescent patients with Hodgkin's lymphoma (HL) are treated either in pediatric, or in adult oncological wards.
  • AIM: The aim of our work was to compare the treatment modalities and the survival rates in adolescents with HL treated in adult (A) or pediatric (P) institutes.
  • METHODS: From January 1990 to December 2004, 138 patients (14-21 years) with HL were treated in two adult institutes (A) and 107 in the 10 centres of the Hungarian Pediatric Oncology Network (P).
  • The distribution of histological subtypes (A and P): nodular sclerosing 47% and 59%, mixed cellularity 45% and 25%, lymphocyte rich 1.5% and 10%, lymphocyte depleted 4% and 1%, nodular lymphocyte predominant 1.5% and 3% and unknown 1% and 2%.
  • Event-free survival was higher in pediatric than in adult institutes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cancer Care Facilities / statistics & numerical data. Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Hungary / epidemiology. Male. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Retrospective Studies. Survival Analysis. Vinblastine / administration & dosage. Vincristine / administration & dosage. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004744.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; OPPA protocol
  •  go-up   go-down


9. Miltényi Z, Simon Z, Páyer E, Váróczy L, Gergely L, Jóna A, Illés A: [Changing patterns in the clinical, pathological features of Hodgkin lymphoma]. Orv Hetil; 2010 Dec 5;151(49):2011-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changing patterns in the clinical, pathological features of Hodgkin lymphoma].
  • [Transliterated title] Változnak-e a Hodgkin-lymphoma klinikopatológiai jellemzői?
  • Hodgkin lymphoma shows a well-known geographic pattern, but temporal changes have been found recently as well.
  • PATIENTS AND METHODS: The Authors analyzed 439 Hodgkin lymphoma patients' clinicopathological and treatment data.
  • RESULTS: The first period contained 117 patients, the second 147 and third 115 Hodgkin lymphoma patients.
  • The incidence of mixed cellularity histological subtype is decreasing; nodular sclerosis shows an increasing tendency.
  • CONCLUSIONS: Changes can be explained by the altered nature of Hodgkin lymphoma, the changes in socioeconomic status and the development of diagnostic and therapy methods.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Female. Humans. Hungary / epidemiology. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Sex Distribution. Socioeconomic Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21106481.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


10. Lechner K, Chen YA: Paraneoplastic autoimmune cytopenias in Hodgkin lymphoma. Leuk Lymphoma; 2010 Mar;51(3):469-74
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic autoimmune cytopenias in Hodgkin lymphoma.
  • We assessed the occurrence, clinical, and laboratory features as well as the response to treatment of autoimmune hemolytic anemia, autoimmune thrombocytopenia, and neutropenia in published cases of Hodgkin lymphomas (HL).
  • The autoimmune cytopenias (AIC) may occur prior to, concurrent with, at the time of recurrence of lymphoma or in complete remission after treatment.
  • Patients with HL with AIC are more commonly males and are more likely to have mixed cellularity (MC) HL.
  • HL is the only lymphoma which may be associated with autoimmune neutropenia.
  • In contrast to AIC in diffuse large B-cell lymphoma (DLBCL), early stage is less common in patients with HL with AIC.
  • [MeSH-major] Autoimmune Diseases / complications. Hodgkin Disease / complications. Neutropenia / complications. Thrombocytopenia / complications
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. PubMed. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141438.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


11. Oshikawa G, Arai A, Sasaki K, Ichinohasama R, Miura O: [Primary multifocal osseous Hodgkin lymphoma]. Rinsho Ketsueki; 2009 Feb;50(2):92-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary multifocal osseous Hodgkin lymphoma].
  • Core needle biopsy of the sternal tumor was performed and a diagnosis of Hodgkin lymphoma (HL) (mixed cellularity) was made.
  • Neither bone marrow biopsy nor cerebrospinal fluid examination showed infiltration of lymphoma cells.
  • [MeSH-major] Bone Neoplasms / diagnosis. Hodgkin Disease / diagnosis. Neoplasms, Multiple Primary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Positron-Emission Tomography. Remission Induction. Tomography, X-Ray Computed. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19265301.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  • [Number-of-references] 15
  •  go-up   go-down


12. Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L: Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol; 2006 Sep;24(3):146-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.
  • This study investigated standardized uptake value (SUV) levels in the different histopathological subtypes of Hodgkin lymphoma (HL).
  • Mean SUV(max/total) was 9.3 g/ml in seven nodular lymphocyte predominance (NLP) patients, 16.3 g/ml in 38 nodular sclerosis (NS) patients, 20.8 g/ml in 11 mixed cellularity (MC) patients, and 19.5 g/ml in four patients with unclassified classical HL (CHL-NOS), (ANOVA, p = 0.011).
  • Mean SUV(max) was 8.3 g/ml in the 12 sites with NLP, 11.2 g/ml in the 147 sites affected with NS, 14.6 g/ml in the 36 sites with MC, and 13.1 g/ml in the 13 sites with CHL-NOS (ANOVA, p = 0.002).
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / radiography. Positron-Emission Tomography
  • [MeSH-minor] Adult. Female. Fluorodeoxyglucose F18 / administration & dosage. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymph Nodes / radiography. Male. Middle Aged. Radiopharmaceuticals / administration & dosage. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 John Wiley & Sons, Ltd.
  • (PMID = 16729353.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Glaser SL, Gulley ML, Clarke CA, Keegan TH, Chang ET, Shema SJ, Craig FE, Digiuseppe JA, Dorfman RF, Mann RB, Anton-Culver H, Ambinder RF: Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations. Int J Cancer; 2008 Oct 1;123(7):1499-507
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations.
  • Epstein-Barr virus (EBV) is detected in the tumor cells of some but not all Hodgkin lymphoma (HL) patients, and evidence indicates that EBV-positive and -negative HL are distinct entities.
  • Therefore, we evaluated EBV presence in the tumors of a large (n = 1,032), racially and sociodemographically diverse series of California incident classical HL cases with uniform pathology re-review and EBV detection methods.
  • In Hispanics, EBV-positive HL was associated not only with young and older age, male sex, and mixed cellularity histology, but also with foreign birth and lower SES in females, suggesting immune function responses to correlates of early childhood experience and later environmental exposures, respectively, as well as of pregnancy.
  • In blacks, EBV-positive HL was associated with later-stage disease, consistent with racial/ethnic variation in certain cytokine polymorphisms.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2000 Apr;34(1):27-53 [10781747.001]
  • [Cites] Isr Med Assoc J. 2000 Jul;2(7):501-3 [10979320.001]
  • [Cites] Hum Immunol. 2000 Aug;61(8):820-7 [10980393.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1522-8 [10995808.001]
  • [Cites] J Epidemiol Community Health. 2000 Dec;54(12):907-11 [11076986.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):705-9 [11401923.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):218-24 [11466672.001]
  • [Cites] Tissue Antigens. 2001 May;57(5):424-39 [11556967.001]
  • [Cites] Am J Epidemiol. 2003 Sep 15;158(6):553-63 [12965881.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] J Clin Pathol. 2003 Nov;56(11):811-6 [14600123.001]
  • [Cites] South Med J. 2004 Mar;97(3):273-7 [15043335.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):243-53 [15090719.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):387-97 [15141139.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S27-32 [15202522.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1361-70 [15298959.001]
  • [Cites] Asian Pac J Cancer Prev. 2004 Jul-Sep;5(3):268-72 [15373705.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] N Engl J Med. 1989 Mar 16;320(11):689-95 [2537928.001]
  • [Cites] Blood. 1993 Jan 15;81(2):462-7 [8380725.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1595-602 [8123850.001]
  • [Cites] Eur J Cancer. 1994;30A(7):1045-6 [7946575.001]
  • [Cites] Int J Cancer. 1995 Apr 10;61(2):165-9 [7705942.001]
  • [Cites] J Infect Dis. 1996 Mar;173(3):529-35 [8627013.001]
  • [Cites] Int J Cancer. 1996 Mar 15;65(6):781-4 [8631592.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2918-29 [8639912.001]
  • [Cites] Soc Sci Med. 1996 Jul;43(1):83-91 [8816013.001]
  • [Cites] Baillieres Clin Haematol. 1996 Sep;9(3):401-16 [8922237.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Histopathology. 1997 Mar;30(3):227-33 [9088951.001]
  • [Cites] Int J Cancer. 1997 Apr 10;71(2):138-41 [9139832.001]
  • [Cites] J Pathol. 1997 Jul;182(3):299-306 [9349232.001]
  • [Cites] Am J Trop Med Hyg. 1998 Nov;59(5):801-7 [9840602.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):604-8 [10408873.001]
  • [Cites] Hum Immunol. 2004 Dec;65(12):1413-9 [15603866.001]
  • [Cites] Brain Behav Immun. 2005 Mar;19(2):91-103 [15664781.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):599-605 [15700307.001]
  • [Cites] Br J Haematol. 2005 May;129(4):511-9 [15877733.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1441-7 [15941953.001]
  • [Cites] Hum Reprod Update. 2005 Jul-Aug;11(4):411-23 [15817524.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):34-41 [16007866.001]
  • [Cites] Cancer Causes Control. 2005 Aug;16(6):713-23 [16049810.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):460-4 [16428487.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):707-13 [16690530.001]
  • [Cites] Cancer Causes Control. 2006 Aug;17(6):771-81 [16783605.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2280-4 [17119058.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):161-8 [17113770.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1297-305 [17322915.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2382-8 [17332371.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):825-40 [17908622.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3310-5 [17630352.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):703-11 [11562110.001]
  • [Cites] Ethn Dis. 2001 Fall;11(4):598-605 [11763284.001]
  • [Cites] Leuk Res. 2002 Mar;26(3):261-9 [11792415.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):259-67 [11863222.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:23-9 [12078898.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):300-9 [12872349.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):298-302 [12949811.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:231-8 [16304386.001]
  • [Cites] Tissue Antigens. 1999 Dec;54(6):533-42 [10674966.001]
  • [Cites] Tissue Antigens. 2000 Jan;55(1):48-52 [10703608.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1117-21 [10737396.001]
  • [Cites] Leukemia. 2000 Apr;14(4):748-53 [10764165.001]
  • (PMID = 18646185.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA065661-03; United States / NCI NIH HHS / CA / R01CA65661; United States / NCI NIH HHS / PC / N01-PC-65107; United States / NCI NIH HHS / PC / N02 PC015105; United States / NCI NIH HHS / CA / R03CA63245; United States / NCI NIH HHS / CA / P50CA096888; United States / NCI NIH HHS / CA / R01 CA065661-03; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS153409; NLM/ PMC2775059
  •  go-up   go-down


14. Ménard F, Besson C, Rincé P, Lambotte O, Lazure T, Canioni D, Hermine O, Brousset P, Martin A, Gaulard P, Raphaël M, Larroche C: Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. Clin Infect Dis; 2008 Aug 15;47(4):531-4
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus.
  • The retrospective study of 34 patients with Hodgkin lymphoma-associated hemophagocytic syndrome led us to define this association as a specific disorder.
  • Its characteristics are male predominance (male-to-female sex ratio, 3.3:1), immunodeficiency-like histological features (lymphocyte depletion, 45% of cases; mixed cellularity Hodgkin lymphoma subtype, 40%), and strong association with Epstein-Barr virus (94%).
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / complications. Hodgkin Disease / virology. Lymphohistiocytosis, Hemophagocytic / etiology. Lymphohistiocytosis, Hemophagocytic / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged


15. Krishnamurthy S, Hassan A, Frater JL, Paessler ME, Kreisel FH: Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease. Int J Surg Pathol; 2010 Aug;18(4):278-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease.
  • Because of its rarity, pathologic and clinical features of Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) are not well understood, and it is unclear whether its biological behavior is more closely related to classical Hodgkin disease or to monomorphic B-cell PTLD.
  • Histologically, all cases of HL-like PTLD resembled classical HL with typical Reed-Sternberg (RS) cells and a cellular background mimicking mixed cellularity subtype.
  • Whereas Epstein-Barr virus early RNA expression is normally restricted to RS cells of classical HL, it was expressed in both RS-like cells and background lymphocytes in HL-like PTLD.
  • Although all patients diagnosed with monomorphic B-cell PTLD show no evidence of disease following treatment, half of the patients with HL-like PTLD relapsed or died, indicating a more aggressive clinical behavior.
  • [MeSH-major] B-Lymphocytes / pathology. Hodgkin Disease / pathology. Lymphoproliferative Disorders / pathology. Organ Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Fatal Outcome. Female. Humans. Immunocompromised Host. Immunosuppression. Immunosuppressive Agents / adverse effects. Male. Middle Aged. Postoperative Complications. RNA-Binding Proteins / metabolism. Reed-Sternberg Cells / metabolism. Reed-Sternberg Cells / pathology. Ribosomal Proteins / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Surg Pathol. 2010 Oct;18(5):444
  • (PMID = 19578050.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunosuppressive Agents; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


16. Chang KC, Chen PC, Jones D, Su IJ: Changing patterns in the frequency of Hodgkin lymphoma subtypes and Epstein-Barr virus association in Taiwan. Cancer Sci; 2008 Feb;99(2):345-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing patterns in the frequency of Hodgkin lymphoma subtypes and Epstein-Barr virus association in Taiwan.
  • Epstein-Barr virus (EBV) infection is a risk factor for Hodgkin lymphoma (HL).
  • Comparing the distribution of HL cases diagnosed at two different time periods, we found an increased frequency of the nodular sclerosis (NS) subtype (53 vs 68%, P = 0.045), a decreased frequency of the mixed cellularity subtype (35 vs 13%, P < 0.001), a reduced male-to-female ratio (2.9:1 compared to 1.4:1) and mean age (42.4 vs 36.6 years) in the NS subtype, and a significant decrease in EBV positivity rates among the NS and lymphocyte-depletion subtypes (61 vs 39%, P = 0.03).
  • [MeSH-major] Epstein-Barr Virus Infections / epidemiology. Hodgkin Disease / epidemiology. Hodgkin Disease / virology
  • [MeSH-minor] Adult. Female. Herpesvirus 4, Human / pathogenicity. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Risk Factors. Taiwan

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18201268.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


17. de Jong D, Bosq J, MacLennan KA, Diebold J, Audouin J, Chasle J, Mandard AM, Marnay J, Henry-Amar M, European Oranization for Research and Treatment of Cancer Lyphoma Group, Groupe d'Etude des Lymphomes de l'Adulte: Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity. Ann Oncol; 2006 Jan;17(1):141-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity.
  • BACKGROUND: To investigate the proportion, clinical characteristics and outcome of lymphocyte-rich classical Hodgkin lymphoma (LRCHL) in relation to nodular lymphocyte predominant HL (NLPHL) and classical HL (cHL).
  • Twenty-one (0.8%) LRCHL cases were identified of which three were originally classified as NLPHL, seven as nodular sclerosis HL (NSHL) and 11 as mixed cellularity (MCHL), indicating that LRCHL is a rare disease.
  • These results strongly suggest that LRCHL corresponds to an early stage in the spectrum of cHL rather than a biologically different disease entity.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284059.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


18. Bazzeh F, Rihani R, Howard S, Sultan I: Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases. Leuk Lymphoma; 2010 Dec;51(12):2198-207
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases.
  • We analyzed data from 18 898 adults (age ≥20 years) and 2836 children/adolescents reported in the Surveillance, Epidemiology and End Results (SEER) database as having Hodgkin lymphoma (HL), diagnosed from 1988 to 2005.
  • The mixed cellularity subtype was more prevalent in children <10 years old (22%), but less likely in older children/adolescents (8.5%).
  • Using a Cox proportional-hazards regression model in patients with classical HL, the prognostic factors significantly impacting survival were age, histology, stage, B symptoms, year of diagnosis, and race.
  • The only adverse prognostic factors that were significant when this analysis was restricted to children/adolescents were stage IV disease and the presence of B symptoms.
  • [MeSH-major] Endpoint Determination / methods. Hodgkin Disease / diagnosis. Hodgkin Disease / epidemiology. Population Surveillance
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Child. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21054151.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Biggar RJ, Johansen JS, Smedby KE, Rostgaard K, Chang ET, Adami HO, Glimelius B, Molin D, Hamilton-Dutoit S, Melbye M, Hjalgrim H: Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res; 2008 Nov 1;14(21):6974-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.
  • We examined serum YKL-40 and IL-6 levels in patients with Hodgkin lymphoma, a tumor with strong immunologic reaction to relatively few tumor cells, especially in nodular sclerosis Hodgkin lymphoma.
  • EXPERIMENTAL DESIGN: We analyzed Danish and Swedish patients with incident Hodgkin lymphoma (N=470) and population controls from Denmark (n=245 for YKL-40; n=348 for IL-6).
  • RESULTS: Serum levels of YKL-40 and IL-6 increased in Hodgkin lymphoma patients compared with controls (YKL-40, 3.6-fold; IL-6, 8.3-fold; both, P<0.0001).
  • In pretreatment samples from pretreatment Hodgkin lymphoma patients (n=176), levels were correlated with more advanced stages (P(trend), 0.0001 for YKL-40 and 0.013 for IL-6) and in those with B symptoms; however, levels were similar in nodular sclerosis and mixed cellularity subtypes, by EBV status, and in younger (<45 years old) and older patients.
  • CONCLUSIONS: Serum YKL-40 and IL-6 levels were increased in untreated Hodgkin lymphoma patients and those with more advanced stages but did not differ significantly by Hodgkin lymphoma histology.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Clin Lab Invest. 2000 Jul;60(4):247-51 [10943594.001]
  • [Cites] Semin Cancer Biol. 2000 Oct;10(5):345-50 [11100882.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4653-65 [14581334.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3216-21 [15070705.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1731-9 [15223630.001]
  • [Cites] Clin Chem. 1998 Mar;44(3):509-16 [9510855.001]
  • [Cites] Biomarkers. 2008 Feb;13(1):59-78 [17852075.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202 [16492905.001]
  • [Cites] Dan Med Bull. 2006 May;53(2):172-209 [17087877.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2382-8 [17332371.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2082-4 [18003965.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • (PMID = 18980992.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069269-02; United States / NCI NIH HHS / CA / S-R01-CA 69269
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / Biomarkers, Tumor; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Interleukin-6; 0 / Lectins
  • [Other-IDs] NLM/ NIHMS80623; NLM/ PMC2613488
  •  go-up   go-down


20. Büyükpamukçu M, Varan A, Akyüz C, Atahan L, Ozyar E, Kale G, Köksal Y, Kutluk T: The treatment of childhood Hodgkin lymphoma: improved survival in a developing country. Acta Oncol; 2009;48(1):44-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of childhood Hodgkin lymphoma: improved survival in a developing country.
  • BACKGROUND: To evaluate the clinical characteristics, treatment regimens, and outcome of children with Hodgkin lymphoma in a developing country over a period of 34 years.
  • METHODS: This paper retrospectively evaluates the treatment and prognosis of 614 children with Hodgkin lymphoma disease between 1971 and 2005.
  • Histopathologic subtypes were mixed cellularity (344 patients), nodular sclerosis (90), lymphocytic predominance (62), lymphocytic depletion (46), unclassified types (69), and nodular lymphocyte predominant Hodgkin lymphoma (3).
  • Over the years, the median age of patients increased, as did the frequency of the nodular sclerosing type of disease.
  • The ABVD protocol yielded the best survival rates and should be used for treatment of patients with Hodgkin lymphoma.
  • [MeSH-major] Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Humans. Male. Multivariate Analysis. Neoplasm Staging. Survival Rate. Treatment Outcome. Turkey / epidemiology. Young Adult


21. Quiñones-Avila Mdel P, Gonzalez-Longoria AA, Admirand JH, Medeiros LJ: Hodgkin lymphoma involving Waldeyer ring: a clinicopathologic study of 22 cases. Am J Clin Pathol; 2005 May;123(5):651-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma involving Waldeyer ring: a clinicopathologic study of 22 cases.
  • We report 22 cases of Hodgkin lymphoma involving Waldeyer ring seen at our institution during a 31-year interval.
  • The 3 patients (14%) whose disease was unstaged had concurrent or a history of non-Hodgkin lymphoma.
  • Histologically, the neoplasms were classified as follows: lymphocyte-rich classical, 8 (36%); nodular sclerosis, 7 (32%); mixed cellularity, 4 (18%); unclassified, 2 (9%); and lymphocyte depletion, 1 (5%).
  • Of 7 stage I cases, 4 (57%) were the lymphocyte-rich classical type.
  • Reed-Sternberg and Hodgkin cells were positive for CD15 and CD30 in 20 cases assessed.
  • We conclude that Hodgkin lymphoma rarely involves Waldeyer ring, with the lymphocyte-rich classical type being common at this location.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Hodgkin Disease / pathology. Lymphoid Tissue / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Female. Herpesvirus 4, Human / isolation & purification. Humans. Male. Middle Aged. Neoplasm Staging. Reed-Sternberg Cells / metabolism. Reed-Sternberg Cells / pathology. Reed-Sternberg Cells / virology. Viral Matrix Proteins / metabolism

  • Genetic Alliance. consumer health - Chromosome 22 Ring.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981804.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


22. Muenst S, Hoeller S, Dirnhofer S, Tzankov A: Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol; 2009 Dec;40(12):1715-22
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.
  • The distribution of PD-1+ lymphocytes in the microenvironment of Hodgkin lymphoma is not random and can serve as a diagnostic marker.
  • We measured the number of PD-1+ lymphocytes in Hodgkin lymphoma and correlated it with the remaining background lymphocyte populations and known biological and clinical key data on a tissue microarray platform encompassing 280 cases of classical Hodgkin lymphoma and 3 cases of nodular lymphocyte-predominant Hodgkin lymphoma.
  • The number of PD-1+ tumor-infiltrating lymphocytes in 189 evaluable cases was median of 27 and mean of 269 cells/mm(2), being higher in lymphocyte-rich classical Hodgkin lymphoma and lower in the mixed cellularity variant.
  • Rimming of tumor cells by PD-1+ cells was observed in all cases of nodular lymphocyte-predominant Hodgkin lymphoma but only in 1% of classical Hodgkin lymphomas, particularly in lymphocyte-rich and -mixed cellularity variants.
  • Thus, the presence of PD-1+ rosettes around neoplastic cells is typical but not exclusive for nodular lymphocyte-predominant Hodgkin lymphoma because it may be encountered in classical Hodgkin lymphoma.
  • The PD-1+ cell amount was lower in classical Hodgkin lymphoma cases with 9p24 gains (PD-1 ligand 2 locus) and in cases with higher numbers of FOXP3+ regulatory T cells.
  • Along with the latter, PD-1+ cells might represent important lymphoma/host microenvironment modulators.
  • [MeSH-major] Antigens, CD / biosynthesis. Apoptosis Regulatory Proteins / biosynthesis. Biomarkers, Tumor / immunology. Hodgkin Disease / immunology. Lymphocytes, Tumor-Infiltrating / immunology. T-Lymphocytes, Helper-Inducer / immunology
  • [MeSH-minor] Adult. Area Under Curve. Female. Forkhead Transcription Factors / biosynthesis. Forkhead Transcription Factors / immunology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Programmed Cell Death 1 Receptor. ROC Curve. T-Lymphocytes, Regulatory / immunology. T-Lymphocytes, Regulatory / metabolism. Tissue Array Analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19695683.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


23. Al-Salam S, John A, Daoud S, Chong SM, Castella A: Expression of Epstein-Barr virus in Hodgkin lymphoma in a population of United Arab Emirates nationals. Leuk Lymphoma; 2008 Sep;49(9):1769-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Epstein-Barr virus in Hodgkin lymphoma in a population of United Arab Emirates nationals.
  • Hodgkin lymphoma (HL) shows wide geographic variation in histological subtypes and in its association with the Epstein-Barr virus (EBV).
  • Other sections were examined for the presence of EBV using the immunohistochemical streptavidin-biotin method for the latent membrane protein 1 and in situ hybridisation for EBV encoded RNA to determine the prevalence of EBV in Hodgkin cells and its possible role in the pathogenesis of HL.
  • Nodular sclerosis (NS) subtype was the most common type of HL among UAE nationals followed by mixed cellularity (MC), lymphocytic predominant (LP), unclassified, lymphocytic depletion (LD) and lymphocyte rich (LR) subtypes, respectively.
  • EBV was seen in 17 of 45 (38%) cases of HL and was predominately seen in the MC subtype followed by NS, LD and LR subtypes, respectively.
  • EBV was more frequently expressed in HL in the pediatric age group than the adult age group.
  • [MeSH-major] Hodgkin Disease / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antigens, CD / analysis. Child. Child, Preschool. Female. Herpesvirus 4, Human. Humans. Immunophenotyping. Incidence. Male. Middle Aged. United Arab Emirates / epidemiology


24. Itoh K, Kinoshita T, Watanabe T, Yoshimura K, Okamoto R, Chou T, Ogura M, Hirano M, Asaoku H, Kurosawa M, Maeda Y, Omachi K, Moriuchi Y, Kasai M, Ohnishi K, Takayama N, Morishima Y, Tobinai K, Kaba H, Yamamoto S, Fukuda H, Kikuchi M, Yoshino T, Matsuno Y, Hotta T, Shimoyama M: Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol; 2010 Apr;91(3):446-55
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.
  • The Japan Clinical Oncology Group conducted two multicenter phase II trials in 200 patients with advanced Hodgkin lymphoma (HL) in the 1990s.
  • Five-year overall survival (OS) among these 167 patients was 88.3%, including 89.2% among nodular sclerosis and 82.2% among mixed cellularity cases.
  • Seven unfavorable prognostic factors for OS on univariate analysis were male, B symptoms, clinical stage of III or IV, elevated serum LDH, elevated alkaline phosphatase, elevated beta2-microglobulin, and pathological subtype (mixed cellularity and lymphocyte depletion).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Clinical Trials, Phase II as Topic / statistics & numerical data. Hodgkin Disease / drug therapy. Hodgkin Disease / mortality. Models, Statistical
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Japan / epidemiology. Kaplan-Meier Estimate. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, Large-Cell, Anaplastic / mortality. Lymphoma, Large-Cell, Anaplastic / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Multicenter Studies as Topic / statistics & numerical data. Multivariate Analysis. Prognosis. Radiotherapy / statistics & numerical data. Remission Induction. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198461.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Rodriguez J, Tirabosco R, Pizzolitto S, Rocco M, Falconieri G: Hodgkin lymphoma presenting with exclusive or preponderant pulmonary involvement: a clinicopathologic study of 5 new cases. Ann Diagn Pathol; 2006 Apr;10(2):83-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma presenting with exclusive or preponderant pulmonary involvement: a clinicopathologic study of 5 new cases.
  • A review of the pathological features of Hodgkin lymphoma manifesting with exclusive or preponderant lung involvement is given for 5 patients.
  • Nodular sclerosing and mixed cellularity were the documented subtypes.
  • Our study confirms that the recognition of Hodgkin lymphoma in lung, although based on well-established morphologic criteria, may represent a source of interpretative problems because of the unusual clinical presentation as well as the peculiar histologic changes induced within the pulmonary microenvironment.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / pathology. Male. Middle Aged. Reed-Sternberg Cells / ultrastructure

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546042.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Darabi K, Sieber M, Chaitowitz M, Braitman LE, Tester W, Diehl V: Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients. Leuk Lymphoma; 2005 Dec;46(12):1715-20
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients.
  • Infradiaphragmatic Hodgkin lymphoma (IDH) accounts for 4-13% of cases of stage I-II Hodgkin lymphoma (HD).
  • It has been associated with distinct pre-treatment characteristics and outcomes when compared with supradiaphragmatic HD (SDH).
  • These two sub-groups of patients were treated in 1988-1993 in 2 prospective randomized clinical trials in Germany for early and intermediate stages of Hodgkin lymphoma.
  • Histology in IDH was more likely to be mixed cellularity (46.5% vs 23.6%, p < 0.001) or lymphocyte predominant (20 vs 10%, p = 0.003) and less likely nodular sclerosis (25% vs 63%, p < 0.001).
  • In early-stage unfavorable disease, IDH was associated with a higher treatment failure rate (unadjusted hazard ratio 2, 95% CI, 1.3-3.4; p = 0.003).
  • [MeSH-major] Hodgkin Disease / physiopathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Diaphragm. Female. Germany. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263573.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Shim HK, Lee WW, Park SY, Kim H, Kim SE: Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma. Oncol Res; 2009;17(7):331-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma.
  • Reed-Sternberg (R-S) cells are the main tumor cells of Hodgkin lymphoma (HL).
  • Three HL patients (mixed cellularity = 2 and nodular sclerosis = 1) demonstrated moderate-strong expressions of Glut-1 in almost all R-S cells, and of these three HL patients, two underwent FDG-PET, which revealed a high level of maxSUVs (7.7, 6.5) in the corresponding HL lesions.
  • In conclusion, high expressions of Glut-1 in R-S cells may play a crucial role for the high FDG uptake in Hodgkin lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Glucose Transporter Type 1 / metabolism. Glucose Transporter Type 3 / metabolism. Hexokinase / metabolism. Hodgkin Disease / metabolism. Hodgkin Disease / radionuclide imaging. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Female. Glucose Transporter Type 2 / metabolism. Humans. Immunoenzyme Techniques. Male. Middle Aged. Positron-Emission Tomography. Reed-Sternberg Cells / radionuclide imaging. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408578.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Glucose Transporter Type 2; 0 / Glucose Transporter Type 3; 0 / Radiopharmaceuticals; 0 / SLC2A2 protein, human; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 2.7.1.1 / Hexokinase
  •  go-up   go-down


28. Huang X, van den Berg A, Gao Z, Visser L, Nolte I, Vos H, Hepkema B, Kooistra W, Poppema S, Diepstra A: Expression of HLA class I and HLA class II by tumor cells in Chinese classical Hodgkin lymphoma patients. PLoS One; 2010;5(5):e10865
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HLA class I and HLA class II by tumor cells in Chinese classical Hodgkin lymphoma patients.
  • BACKGROUND: In Caucasian populations, the tumor cells of Epstein Barr virus (EBV)-positive classical Hodgkin Lymphomas (cHL) patients more frequently express HLA class I and HLA class II molecules compared to EBV-negative cHL patients.
  • As expected, the percentage of EBV+ cases was much higher in the mixed cellularity subtype (71%) than in the nodular sclerosis subtype (16%) (p<0.001).
  • [MeSH-major] Asian Continental Ancestry Group. Histocompatibility Antigens Class I / immunology. Histocompatibility Antigens Class II / immunology. Hodgkin Disease / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. China. Female. Herpesvirus 4, Human / immunology. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Netherlands. RNA, Viral / genetics. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2002 Aug 15;169(4):2172-9 [12165547.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Methods. 2003 Mar;29(3):227-35 [12725788.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] J Immunol. 1986 Oct 1;137(7):2299-306 [3760563.001]
  • [Cites] Blood. 1996 May 1;87(9):3844-51 [8611711.001]
  • [Cites] Int J Cancer. 1997 Aug 7;72(4):614-8 [9259400.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1020-30 [9680372.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2477-83 [9746788.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] Int J Hematol. 2006 Jun;83(5):391-7 [16787868.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3101-8 [17536082.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3310-5 [17630352.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):685-91 [18245527.001]
  • [Cites] Tissue Antigens. 2008 Mar;71(3):219-26 [18257895.001]
  • [Cites] Oncogene. 2008 Oct 6;27(45):5869-85 [18836468.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):528-36 [19017177.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7195-9 [12499257.001]
  • (PMID = 20526359.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / Epstein-Barr virus encoded RNA 2; 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II; 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC2878318
  •  go-up   go-down


29. Clarke CA, Glaser SL, Keegan TH, Stroup A: Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev; 2005 Jun;14(6):1441-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California.
  • Hodgkin's lymphoma occurrence has long been noted to associate with higher socioeconomic status (SES).
  • However, the Hodgkin's lymphoma-SES association has not been examined recently or across important, possibly etiologically distinct, patient subgroups.
  • In approximately 150 million person-years of observation in the multiethnic population of California, we examined the association of Hodgkin's lymphoma incidence with a composite measure of neighborhood-level SES in patient subgroups defined by age, sex, race/ethnicity, and Hodgkin's lymphoma histologic subtype.
  • Using population-based cancer registry data on 3,794 Hodgkin's lymphoma patients diagnosed 1988 to 1992 and 1990 census data, we assigned a previously validated, multidimensional SES index to census block groups of patient residence.
  • Positive neighborhood SES gradients in Hodgkin's lymphoma incidence were observed only in young adults (ages 15-44 years at diagnosis) with nodular sclerosis Hodgkin's lymphoma and older adult (ages > or =45 years) White and Hispanic males with mixed cellularity Hodgkin's lymphoma.
  • Neighborhood SES gradients in Hodgkin's lymphoma incidence varied by age, sex, race/ethnicity, and histologic subtype, underscoring etiologic complexity in Hodgkin's lymphoma.
  • In California, etiologically relevant exposures for young adult Hodgkin's lymphoma, the most common form, could associate more with race/ethnicity or foreign birthplace than neighborhood SES and may be modified by reproductive or other sex-specific factors.
  • [MeSH-major] Hodgkin Disease / economics. Hodgkin Disease / epidemiology. Registries / statistics & numerical data. Social Class
  • [MeSH-minor] Adolescent. Adult. Aged. California / epidemiology. Child. Child, Preschool. Continental Population Groups. Ethnic Groups. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Residence Characteristics. Risk Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941953.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Wang JF, Wang YZ, Chen ZW, Taylor RC: [Prevalence of lymphoma subtypes in Shanxi according to latest WHO classification]. Zhonghua Bing Li Xue Za Zhi; 2006 Apr;35(4):218-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prevalence of lymphoma subtypes in Shanxi according to latest WHO classification].
  • OBJECTIVE: To analyze the prevalence of lymphoma subtypes in Shanxi according to the latest World Health Organization (WHO) classification, and to compare the figures with those in other parts of the world.
  • METHODS: The hematoxylin and eosin-stained sections of 447 lymphoma cases from the archive files of Shanxi Tumor Hospital were reviewed.
  • All cases were then reclassified according to the latest WHO classification of lymphoma.
  • RESULTS: Of the 447 cases studied, 385 cases (86.1%) were confirmed to be non-Hodgkin lymphoma (NHL), while 62 cases (13.9%) belonged to classic Hodgkin lymphoma (HL).
  • As for the subtyping of NHL, diffuse large B-cell lymphoma was commonest (35.1%), followed by peripheral T-cell lymphoma, NOS (12.0%), extranodal marginal zone B-cell lymphoma (MALT lymphoma) (11.7%), follicular lymphoma (8.6%), T-lymphoblastic lymphoma (7.0%), anaplastic large cell lymphoma (4.2%), B-small lymphocytic lymphoma (3.6%) and mantle cell lymphoma (2.6%).
  • Amongst the 263 cases of B-cell lymphoma, 105 cases (39.9%) expressed immunoglobulin light chain (kappa in 52 cases and lambda in 53 cases) in paraffin sections.
  • Regarding markers for EB virus infection, 14 cases of the B-cell lymphoma gave positive findings with both EBER in-situ hybridization and LMP-1 immunohistochemistry, while 6 of the T/NK-cell lymphoma expressed LMP-1 and 19 showed positive signals for EBER.
  • As for HL, EB virus positivity was noted in 37 of the 62 cases (59.7%), including 7 cases of lymphocyte-rich HL, 11 cases of mixed cellularity HL and 19 cases of nodular sclerosis HL.
  • CONCLUSIONS: The prevalence of diffuse large B-cell lymphoma in Shanxi is similar to that in America, Australia, Japan and Korea.
  • The incidence of follicular lymphoma however is much lower than America and Australia.
  • [MeSH-major] Hodgkin Disease / classification. Lymphoma / classification. Lymphoma, Non-Hodgkin / classification. World Health Organization
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. China / epidemiology. Female. Humans. Immunohistochemistry. Infant. Lymphoma, Follicular / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Prevalence. Young Adult


31. Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ: [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2008 Aug;30(8):630-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
  • OBJECTIVE: To compare the efficacy of chemotherapy alone, radiotherapy alone and combined-modality therapy in the treatment for early-stage Hodgkin's lymphoma (HL).
  • RESULTS: The pathological types included nodular sclerosis (NS, n = 84), mixed-cellularity (MC, n = 39), lymphocyte-predominant (LP, n = 23), lymphocyte-depleted (LD, n = 3) and nodular lymphocyte predominant Hodgkin's disease (NLPHD, n = 1).
  • There were 33 patients with complete response (CR), 109 with partial response (PR), 5 with stable disease (SD) and 3 with progressive disease (PD) after initial therapy.
  • The response rate of CMT group was superior to that of CT group, and the patients with nodular sclerosis or mixed-cellularity type had significantly lower risk of treatment failure (P = 0.009 and 0.019, respectively).
  • CONCLUSION: Combined-modality therapy is more effective than chemotherapy alone or radiotherapy alone in the treatment for early stage Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Bleomycin / adverse effects. Bleomycin / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Dacarbazine / adverse effects. Dacarbazine / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vinblastine / adverse effects. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use. Young Adult


32. Karube K, Ohshima K, Suzumiya J, Kawano R, Kikuchi M, Harada M: Gene expression profile of cytokines and chemokines in microdissected primary Hodgkin and Reed-Sternberg (HRS) cells: high expression of interleukin-11 receptor alpha. Ann Oncol; 2006 Jan;17(1):110-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profile of cytokines and chemokines in microdissected primary Hodgkin and Reed-Sternberg (HRS) cells: high expression of interleukin-11 receptor alpha.
  • We microdissected Hodgkin and Reed-Sternberg (HRS) cells from 14 Hodgkin's lymphoma tissue samples (nodular sclerosis = 5; mixed cellularity = 9), and after isolation and amplification of mRNA, analyzed the expression profile of 140 genes of chemokines, cytokines and their receptors by cDNA microarray methods.
  • In contrast, only few cases were positive for IL-11Ralpha in B cell lymphoma, diffuse large cell lymphoma and follicular lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291580.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokines; 0 / Cytokines; 0 / IL11RA protein, human; 0 / Interleukin-11 Receptor alpha Subunit; 0 / RNA, Messenger; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-11
  •  go-up   go-down


33. Lacroix A, Jaccard A, Rouzioux C, Piguet C, Petit B, Bordessoule D, Ranger-Rogez S: HHV-6 and EBV DNA quantitation in lymph nodes of 86 patients with Hodgkin's lymphoma. J Med Virol; 2007 Sep;79(9):1349-56
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HHV-6 and EBV DNA quantitation in lymph nodes of 86 patients with Hodgkin's lymphoma.
  • In particular, both viruses are found in lymph nodes of patients suffering from Hodgkin's lymphoma.
  • The aim of this study was to detect and to quantify independently HHV-6 and EBV by a real-time PCR in lymph nodes from 86 patients with Hodgkin's lymphoma.
  • EBV genome was detected for 61.6% of the patients (53/86) and the highest prevalence of this virus was observed in Hodgkin's lymphoma with mixed-cellularity histopathological type (80%).
  • [MeSH-major] Herpesviridae Infections / virology. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Herpesvirus 6, Human / genetics. Herpesvirus 6, Human / isolation & purification. Hodgkin Disease / virology. Lymph Nodes / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. DNA, Viral / analysis. Female. Follow-Up Studies. Humans. Male. Middle Aged. Viral Matrix Proteins / analysis. Viral Matrix Proteins / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607791.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


34. Othieno-Abinya NA, Abwao HO, Opiyo A, Njuguna E, Maina JM, Nyabola LO: Hodgkin's lymphoma in the 1990s: a Kenyatta National Hospital experience. East Afr Med J; 2005 Feb;82(2):59-65
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in the 1990s: a Kenyatta National Hospital experience.
  • OBJECTIVE: To re-evaluate clinico-pathologic categorisation of patients with Hodgkin's lymphoma, treatments offered and their appropriateness, and outcome of this disease at Kenyatta National Hospital in the 1990s.
  • DESIGN: Retrospective survey of Hodgkin's lymphoma patients aged 13 years and above at the Kenyatta National Hospital.
  • SUBJECTS: Patients aged 13 years and above, with diagnosis of Hodgkin's lymphoma.
  • 14.2% of the cases were of lymphocyte predominant histologic subtype, 23.6% nodular sclerosis, 26.4% mixed cellularity and 17% Lymphocyte depletion (Rye Modification of Lukes and Butler Classification).
  • Disease stages IIIB, IVA and IVB (Ann Arbor) were found in 24.5% of the cases.
  • Complete remission was realised in 56% of the cases and most cases were lost to follow-up, making it difficult to correlate survival with known prognostic parameters, apart from early stage disease and attainment of complete remission which correlated with prolonged durations of follow-up.
  • Early disease stage and attainment of complete remission appeared to correlate with longer follow-up duration.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Kenya. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122093.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Kenya
  •  go-up   go-down


35. Qiu YZ, Tian YQ, Ai WB, Xiao JY, Zhao SP: [Clinical analysis of 170 cases head and neck lymphoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Dec;31(6):921-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 170 cases head and neck lymphoma].
  • OBJECTIVE: To study the characteristics of head and neck lymphoma in order to improve its diagnose rate.
  • METHODS: Review and analysis 170 patients with head and neck lymphoma in department of otolaryngology of Xiangya hospital from 1997 to 2005.
  • RESULTS: Nasal cavity and nasal sinuses, neck, tonsil were the common place of the origin of head and neck lymphoma.
  • There are 9 cases Hodgkin disease and 161 cases non-Hodgkin lymphoma (NHL).
  • T cellularity, B cellularity lymphoma, the mixed pattern and nullityping accounted for 60.9%, 36.0% and 3.1% of these patients with NHL, respectively.
  • CONCLUSION: The clinical and imageology manifestation of head and neck lymphoma were of diversification and no specificity, whose final diagnosis depended on immunohistochemistry.
  • [MeSH-major] Head and Neck Neoplasms. Lymphoma
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213611.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


36. Wu SJ, Chen CY, Su IJ, Tang JL, Chou WC, Ko BS, Huang SY, Yao M, Tsay W, Chen YC, Wang CH, Tien HF: Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan. J Formos Med Assoc; 2008 Jan;107(1):4-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan.
  • BACKGROUND/PURPOSE: Hodgkin's lymphoma (HL) is particularly rare in Asia, including Taiwan.
  • RESULTS: The age distribution revealed a young-adult peak at the age around 20 years.
  • The nodular sclerosis type (NS-HL) was the most common histopathologic subtype (45%), followed by mixed cellularity (29%), lymphocyte predominant (13%), and lymphocyte depleted subtype (2%).

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18218572.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


37. Kwon JM, Park YH, Kang JH, Kim K, Ko YH, Ryoo BY, Lee SS, Lee SI, Koo HH, Kim WS: The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol; 2006 Jul;85(7):463-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma.
  • The association of Epstein-Barr virus (EBV) with Hodgkin's lymphoma (HL) has been investigated over the last few years.
  • EBER-positive HL were significantly more frequent in mixed cellularity (MC) subtype (P=0.014) and advanced stage (P=0.034).
  • LMP1 expression also correlated with MC subtype (P=0.006) and advanced stage (P=0.007), although it did not significantly influence the survival outcome.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Male. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16534596.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Keresztes K, Miltenyi Z, Bessenyei B, Beck Z, Szollosi Z, Nemes Z, Olah E, Illes A: Association between the Epstein-Barr virus and Hodgkin's lymphoma in the North-Eastern part of Hungary: effects on therapy and survival. Acta Haematol; 2006;116(2):101-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between the Epstein-Barr virus and Hodgkin's lymphoma in the North-Eastern part of Hungary: effects on therapy and survival.
  • This retrospective study included 109 patients with Hodgkin's lymphoma (HL; 45 females, 64 males).
  • The highest virus association (50%) was found with the mixed cellularity histologic subtype, especially in patients aged 11-20 and >50 years.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / complications
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Herpesvirus 4, Human / isolation & purification. Humans. Hungary. Infant. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16914904.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


39. Haddadin WJ: Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification. Ann Saudi Med; 2005 Sep-Oct;25(5):398-403
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification.
  • BACKGROUND: Most studies describing the subtypes of lymphoma in Jordan were carried out in the 1980s at a time when immunohistochemical facilities were unavailable.
  • Using a database established after immunohistochemical studies were introduced, we determined the frequency of the various types of nodal and extranodal lymphomas in the adult and paediatric Jordanian population.
  • We also assessed the incidence of bone marrow involvement at the initial presentation for each lymphoma type.
  • METHODS: A retrospective analysis of the histopathological subtypes of various lymphomas was conducted on all primary lymphoma cases diagnosed during a 3-year period between January 2001 and December 2003.
  • RESULTS: Of 347 patients included in the study, 78.4% had non-Hodgkin's lymphoma (NHL) and 21.6% had Hodgkin's lymphoma (HL).
  • In the NHL group, diffuse large B-cell lymphoma was the most common (28.2%) followed by follicular lymphoma (15.6%).
  • In the HL group, the nodular sclerosis variant was the most frequent (7.8%) followed by the mixed cellularity type (5.5%).
  • Of all the lymphoma cases, the highest incidence of marrow involvement was seen in patients with lymphoplasmacytic lymphoma.
  • Forty-nine patients were children (age <15 years) in whom Burkitt's lymphoma (15 cases) and HL (14 cases) were the commonest subtypes.
  • Among the various lymphomas, diffuse large B-cell lymphoma is the most commonly encountered lymphoma in adults.
  • Burkitt's lymphoma and Hodgkin's disease are the most frequent childhood lymphomas, followed closely by lymphoblastic lymphoma.
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Incidence. Jordan / epidemiology. Male. Middle Aged. Retrospective Studies. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270763.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


40. Vassallo J, Paes RP, Soares FA, Menezes Y, Aldred V, Ribeiro Kde C, Alves AC: Histological classification of 1,025 cases of Hodgkin's lymphoma from the State of São Paulo, Brazil. Sao Paulo Med J; 2005 May 2;123(3):134-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological classification of 1,025 cases of Hodgkin's lymphoma from the State of São Paulo, Brazil.
  • CONTEXT AND OBJECTIVE: It is currently asserted that, in industrialized countries, nodular sclerosis is the most frequent type of Hodgkin's lymphoma, in contrast to developing countries, where mixed cellularity and lymphocyte depletion are more frequently seen.
  • The objective was to review histological data from cases of Hodgkin's lymphoma from São Paulo and Campinas cities.
  • METHODS: 1,025 cases diagnosed as Hodgkin's lymphoma between 1990 and 2000 were collected from five institutions; 631 of them (61.5%) had been immunophenotyped using antibodies to CD20, CD3, CD15 and CD30.
  • RESULTS: The Hodgkin's lymphoma types were distributed as follows: lymphocyte predominance 4.8%, nodular sclerosis 69.2%, mixed cellularity 21.1% and lymphocyte depletion 4.6%.
  • CONCLUSIONS: The controversy regarding the frequencies of Hodgkin's lymphoma types within the Brazilian setting seems to be due to the small number of cases in previous studies.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Brazil. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Sex Distribution

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16021277.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Niitsu N, Nakamine H, Okamoto M, Tamaru JI, Hirano M: A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma. Ann Oncol; 2008 Nov;19(11):1941-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma.
  • BACKGROUND: We carried out immunohistochemistry to examine the expression of nm23-H1 in Hodgkin and Reed-Sternberg cells in patients with classical Hodgkin's lymphoma (CHL).
  • PATIENTS AND METHODS: We evaluated 128 patients with CHL [87 patients with nodular sclerosis (NS) and 41 patients with mixed cellularity (MC)] for CD15, CD20, Ki-67, EBER, TIA-1, and nm23-H1 by immunohistochemistry.
  • NS patients showed a significantly higher rate of nm23-H1 expression than MC patients (P < 0.001).

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647967.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


42. Souza EM, Baiocchi OC, Zanichelli MA, Alves AC, Assis MG, Eiras DP, Dobo C, Oliveira JS: Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's lymphoma in Brazil. Hematol Oncol; 2010 Sep;28(3):137-41
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's lymphoma in Brazil.
  • INTRODUCTION: Classical Hodgkin's Lymphoma (cHL) has been frequently associated with Epstein-Barr virus (EBV), which can be found in a latent pattern in Reed-Sternberg (RS) cells.
  • Mixed cellularity (MC) subtype was more common in EBV-related tumours (25.5%) (p=0.005).
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Brazil. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20128016.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


43. Siddiqui N, Ayub B, Badar F, Zaidi A: Hodgkin's lymphoma in Pakistan: a clinico-epidemiological study of 658 cases at a cancer center in Lahore. Asian Pac J Cancer Prev; 2006 Oct-Dec;7(4):651-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in Pakistan: a clinico-epidemiological study of 658 cases at a cancer center in Lahore.
  • OBJECTIVES: To study the clinico-epidemiological profile of Hodgkin's lymphoma (HL) in Pakistan.
  • Histopathologically, mixed cellularity (MC) constituted 63.8% of cases, followed by nodular sclerosis (NS) 19.9%, lymphocyte predominant (LP) 7.3% and lymphocyte depleted (LD) 1.2%.
  • Early stage (stage I and II) disease was present in 43.9% of patients at presentation, while 56.1% patients presented with advanced stage (stage III and IV).
  • CONCLUSION: The clinico-epidemiological pattern of Hodgkin's lymphoma in Pakistan manifested is similar to that observed in other developing countries, with male predominance, mixed cellularity as the commonest histological type, advanced stage at presentation and absence of bimodal age distribution.
  • [MeSH-major] Hodgkin Disease / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Neoplasm Staging. Pakistan / epidemiology. Registries. Retrospective Studies. Seasons. Social Class

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17250446.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


44. Al-Kuraya K, Narayanappa R, Al-Dayel F, El-Solh H, Ezzat A, Ismail H, Belgaumi A, Bavi P, Atizado V, Sauter G, Simon R: Epstein-Barr virus infection is not the sole cause of high prevalence for Hodgkin's lymphoma in Saudi Arabia. Leuk Lymphoma; 2006 Apr;47(4):707-13
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus infection is not the sole cause of high prevalence for Hodgkin's lymphoma in Saudi Arabia.
  • The age-adjusted incidence of Hodgkin's lymphoma (HL) is markedly higher in Saudi Arabia than in the USA, and accounts for 10.5% of all neoplasias in children aged 15 years or older in Saudi Arabia.
  • Within the Saudi Arabian population, EBV infection was most frequently seen in mixed cellularity HL (52.4%).
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / virology
  • [MeSH-minor] Adolescent. Adult. Child. Disease Susceptibility. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Prevalence. Saudi Arabia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690530.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. Claviez A, Tiemann M, Lüders H, Krams M, Parwaresch R, Schellong G, Dörffel W: Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma. J Clin Oncol; 2005 Jun 20;23(18):4048-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma.
  • PURPOSE: The prognostic significance of latent Epstein-Barr virus (EBV) infection in Hodgkin's lymphoma (HL) is debated controversially.
  • PATIENTS AND METHODS: Eight hundred forty-two children and adolescents (median age, 13.7 years) from pediatric multicenter treatment studies HD-90 and HD-95 were studied for latent EBV infection in Hodgkin's and Reed-Sternberg cells by immunostaining against latent membrane protein 1 (LMP-1).
  • EBV infection correlated with sex (39% male v 23% female; P < .001), histologic subtype (69% mixed cellularity v 22% nodular sclerosis v 6% lymphocyte predominance; P < .001) and young age.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / virology. Viral Matrix Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Prognosis. Proportional Hazards Models. Reed-Sternberg Cells / virology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15961758.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


46. Adelusola KA, Titiloye NA, Rotimi O, Durosinmi M: Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians. Afr Health Sci; 2009 Sep;9(3):174-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians.
  • The rest were non-Hodgkin's lymphoma (2 diffuse large B-cell and 1 null cell ALCL).
  • All were cases of classical HL with 60% being of the mixed cellularity (MC) subtype.
  • 60% of the tumour was EBV positive, all of the MC subtype.
  • CONCLUSION: Mixed cellularity is the most common subtype and is the only subtype associated with EBV positivity in this study.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / virology. Viral Matrix Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, CD15 / immunology. Antigens, CD30 / immunology. Biomarkers, Tumor / immunology. Child. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Immunophenotyping. Male. Nigeria. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pathol. 2000 Oct;53(5):262-9 [11091850.001]
  • [Cites] Histopathology. 2008 May;52(6):775-7 [18439160.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):566-73 [12808062.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Afr J Med Med Sci. 1992 Oct;21(1):79-83 [1288248.001]
  • [Cites] Leukemia. 1994 Apr;8 Suppl 1:S77-82 [8152310.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):615-7 [15916683.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):55-62 [16007870.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):747-55 [16084943.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):395-405 [11523539.001]
  • (PMID = 20589147.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC2887026
  • [Keywords] NOTNLM ; Epstein-Barr virus / Hodgkin's lymphoma in Nigerians
  •  go-up   go-down


47. Lee MY, Tan TD, Feng AC: Clinico-pathological study of Hodgkin's lymphoma in a cancer center in Taiwan. Clin Lab Haematol; 2005 Dec;27(6):379-83
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathological study of Hodgkin's lymphoma in a cancer center in Taiwan.
  • The incidence rate of Hodgkin's lymphoma (HL) in Asia is much lower than that of western countries.
  • The incidence rate of HL in malignant lymphoma in our center was 7%.
  • Mixed cellularity, lymphocyte rich, lymphocyte depletion, nodular lymphocyte predominance and unclassified was 4.8%, 4.8%, 0%, 7% and 14% respectively.
  • Clinically, 1 (2%) had stage I disease, 23 (55%) stage II, 8 (19%) stage III and 10 (24%) stage IV.
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Cancer Care Facilities. Child. Female. Humans. Incidence. Lymphocytes / pathology. Male. Middle Aged. Neoplasm Staging / statistics & numerical data. Prognosis. Sclerosis. Survival Analysis. Taiwan / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16307539.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Niitsu N, Okamoto M, Tomita N, Aoki S, Tamaru J, Miura I, Hirano M: Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma. Leuk Lymphoma; 2006 Sep;47(9):1908-14
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma.
  • A German Hodgkin's lymphoma (HL) study group designed the BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone) regimen.
  • In the BEACOPP regimen, treatment intervals were shortened and the dose-intensity was increased compared with those in the ABVD regimen (doxorubicin, bleomycin, vinblastine and darcarbacine), resulting in a long-term disease-free survival rate of approximately 75-80%.
  • The histologic types were mixed cellularity in four cases and nodular sclerosis in 16 cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Procarbazine / therapeutic use. Treatment Outcome. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065005.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol
  •  go-up   go-down


49. Linck D, Lentini G, Tiemann M, Fauser AA, Parwaresch R, Basara N: Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma. Leuk Lymphoma; 2005 Feb;46(2):285-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma.
  • We describe successful treatment of a 38-year-old patient with composite lymphoma stage IV(A), who presented with multifocal enlarged lymph nodes.
  • The lymph node histology showed classic morphologic features of Hodgkin's disease, mixed cellularity subtype and follicular B-cell lymphoma.
  • The areas of Hodgkin's disease demonstrated positive immunoreactivity for CD30 and CD20 in the Hodgkin's cells.
  • Restaging after chemotherapy showed radiological partial remission, but biopsy confirmed persisting follicular B-cell lymphoma without bone marrow infiltration and no evidence of Hodgkin's disease.
  • He was treated with monoclonal CD 20-antibody (Rituximab) 10 mg/kg weekly for eight consecutive weeks due to marked positivity of CD 20-antigen in follicular lymphoma cells.
  • This treatment was well tolerated and final staging showed complete remission of the composite lymphoma.
  • In conclusion, in the very rare case of composite lymphoma a combination of chemotherapy and subsequent immunotherapy might be considered as a promising therapeutic option.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology. Humans. Ki-67 Antigen. Leukemia, Lymphoid / drug therapy. Leukemia, Lymphoid / pathology. Male. Neprilysin. Remission Induction / methods. Rituximab

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621815.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Ki-67 Antigen; 4F4X42SYQ6 / Rituximab; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


50. Asano N, Oshiro A, Matsuo K, Kagami Y, Ishida F, Suzuki R, Kinoshita T, Shimoyama Y, Tamaru J, Yoshino T, Kitamura K, Fukutani H, Morishima Y, Nakamura S: Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study. J Clin Oncol; 2006 Oct 1;24(28):4626-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study.
  • PURPOSE: Classical Hodgkin's lymphoma (CHL) is characterized by Hodgkin's and Reed-Sternberg (H-RS) cells, most of which are derived from germinal-center B cells.
  • PATIENTS AND METHODS: Participants were 324 consecutive CHL patients, comprising 132 patients with nodular sclerosis (NS), 35 patients with NS grade 2 (NS2), and 157 patients with mixed cellularity (MC).
  • Morphologic subtyping (NS/NS2/MC) and Epstein-Barr virus positivity were not identified as independent prognostic factors.
  • [MeSH-major] Hodgkin Disease / blood. Hodgkin Disease / diagnosis. T-Lymphocytes / metabolism. T-Lymphocytes, Cytotoxic / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Immunophenotyping / methods. In Situ Hybridization. Male. Middle Aged. Phenotype. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954517.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Trimèche M, Bonnet C, Korbi S, Boniver J, de Leval L: Association between Epstein-Barr virus and Hodgkin's lymphoma in Belgium: a pathological and virological study. Leuk Lymphoma; 2007 Jul;48(7):1323-31
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between Epstein-Barr virus and Hodgkin's lymphoma in Belgium: a pathological and virological study.
  • The association between Epstein-Barr virus (EBV) and classical Hodgkin's lymphoma (cHL) varies according to the geographic location.
  • EBV positivity correlated with older age at diagnosis (>54 years; p = 0.01), mixed cellularity subtype (p = 0.000001), male gender (p = 0.004) and tended to be associated with higher clinical stage (III/IV; p = 0.02).
  • [MeSH-major] Herpesvirus 4, Human / genetics. Hodgkin Disease / virology. Viral Matrix Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Belgium / epidemiology. Child. Epstein-Barr Virus Infections / diagnosis. Female. Humans. Male. Middle Aged. Palatine Tonsil / virology. Prevalence. Reed-Sternberg Cells / virology. Risk Factors. Sequence Deletion

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613761.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


52. Corti M, Fioti MF, Yampolsky C, Schtirbu R, Narbaitz M: Central nervous system involvement in Hodgkin's lymphoma associated with Epstein-Barr virus in a patient with AIDS: case report and review of the literature. Braz J Infect Dis; 2006 Dec;10(6):403-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in Hodgkin's lymphoma associated with Epstein-Barr virus in a patient with AIDS: case report and review of the literature.
  • Intracranial and intraspinal involvement is a rare complication of Hodgkin's disease.
  • We report a case of a patient with diagnosis of AIDS and Hodgkin's lymphoma who developed brain and spinal involvement at the time of the relapse of the neoplasm disease.
  • Mixed cellularity histology was the subtype of Hodgkin's disease in our patient; we identified the Epstein-Barr virus genome in the Reed-Sternberg cells by immunohistochemistry and in situ hybridization.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Central Nervous System Neoplasms / complications. Epstein-Barr Virus Infections / complications. Hodgkin Disease / complications
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Immunohistochemistry. In Situ Hybridization. Magnetic Resonance Imaging. Male. Reed-Sternberg Cells / virology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17420914.001).
  • [ISSN] 1413-8670
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 17
  •  go-up   go-down


53. Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ: LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant; 2007 Jan;39(1):41-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
  • High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a recognized treatment option for patients with relapsed Hodgkin's lymphoma.
  • We have analysed 67 patients who underwent ASCT after LACE (lomustine (CCNU), cytarabine (Ara-C), cyclophosphamide, etoposide) conditioning for relapsed (n=61) or primary refractory (n=6) Hodgkin's lymphoma.
  • In multivariate analysis mixed cellularity classical or lymphocyte-depleted classical histology subtype and haemoglobin level of 10 g/dl or less at the time of ASCT were identified as risk factors for worse OS, whereas stage III or IV disease at diagnosis and disease status at ASCT other than complete or partial remission predicted inferior PFS.
  • LACE followed by ASCT is an effective treatment for the majority of patients with chemosensitive relapsed Hodgkin's lymphoma and a proportion of chemorefractory patients also benefit.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Recurrence. Retrospective Studies. Time Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17115062.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


54. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V, Josting A: Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol; 2005 Aug 20;23(24):5739-45
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
  • PURPOSE: To investigate the clinical characteristics and treatment outcome of patients with lymphocyte-rich classical Hodgkin's lymphoma (LRCHL) compared with other histologic subtypes of Hodgkin's lymphoma (HL).
  • PATIENTS AND METHODS: From a total of 2,715 patients with biopsy-proven HL treated within the trials HD7 to HD12 of the German Hodgkin's Study Group, 100 patients (4%) with LRCHL, 145 patients (5%) with lymphocyte-predominant HL (LPHL), 1,688 patients (62%) with nodular sclerosis, 731 patients (27%) with mixed cellularity, and 23 patients (1%) with lymphocyte depletion were identified.
  • RESULTS: Compared with other histologic subtypes, patients with LRCHL are, on average, older and usually present with early stages of disease (stage I, 34%; stage II, 46%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Disease Progression. Female. Germany. Humans. Lymphocytes. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 May 10;24(14):2220
  • (PMID = 16009944.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, López-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H, GESIDA Group, GELCAB Group: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica; 2007 Feb;92(2):191-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Although doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is considered the standard chemotherapy regimen for Hodgkin's lymphoma (HL), information on the results of this therapy in human immunodeficiency (HIV)-related HL is scarce.
  • The histologic subtype of HL was nodular sclerosis in 17 patients (27%), mixed cellularity in 25 (41%), lymphocyte depletion in 10 (16%) and non-specified in the remaining 10 (16%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Hodgkin Disease / virology. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. CD4-Positive T-Lymphocytes / metabolism. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296568.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


56. Osorio S G, Montenegro U C: [Lymphomas and HIV infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review]. Rev Chilena Infectol; 2007 Apr;24(2):117-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The association of HIV infection and lymphoma in patients attending at the South Health Metropolitan Reference Centre is presented.
  • RESULTS: 14 cases were detected, 10 non Hodgkin lymphoma patients (7 with high malignancy and 50% in stages III-IVB) and 4 with Hodgkin lymphoma (3 with mixed cellularity, 2 in stage IVB).
  • Eighty six percent of patients presented with unique or multiples lymphonodes, with predominance of advanced lymphoma stage.
  • Conventional CHOP chemotherapy was the treatment for high risk and extended non Hodgkin lymphomas and for extended Hodgkin lymphomas the ABVD protocol was administered.
  • Global mortality in this series was 71%, attributable to tumor disease per se or to sepsis.
  • Four patients survived (18 to 50 months) in complete remission, 2 non Hodgkin lymphomas and 2 Hodgkin lymphomas.
  • The low incidence of lymphoma and AIDS association and the high frequency of lymphomas with localized or generalized lymphonodes in this series are remarkable.
  • [MeSH-major] Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Chile / epidemiology. Female. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy. Hodgkin Disease / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453069.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 30
  •  go-up   go-down


57. Bosch Príncep R, Lejeune M, Salvadó Usach MT, Jaén Martínez J, Pons Ferré LE, Alvaro Naranjo T: Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma. Ann Hematol; 2005 Oct;84(10):661-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma.
  • This study aimed to assess the differences in the cellular composition of the inflammatory reactive background around tumoral cells of classical Hodgkin's lymphomas (cHL) inside and outside the HIV settings.
  • Our clinical and histological data indicate that HIV-infected cHL patients present a higher frequency of mixed cellularity (MC) histological subtypes, more advanced disease stages, a poor response to treatment, and a poor overall survival compared to control patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. CD8-Positive T-Lymphocytes / metabolism. HIV. HIV Infections / metabolism. Hodgkin Disease / metabolism. Serine Endopeptidases / metabolism
  • [MeSH-minor] Adult. CD4-CD8 Ratio / methods. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. CD4-Positive T-Lymphocytes / virology. Female. Granzymes. Humans. Inflammation / metabolism. Inflammation / pathology. Inflammation / virology. Male. Middle Aged. Poly(A)-Binding Proteins. RNA-Binding Proteins / metabolism. Retrospective Studies


58. Hashemi-Bahremani M, Parwaresch MR, Tabrizchi H, Gupta RK, Raffii MR: Lymphomas in Iran. Arch Iran Med; 2007 Jul;10(3):343-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the histochemical methods, the immunohistochemical markers were used to examine the biopsied specimens of 434 patients with non-Hodgkin's and Hodgkin's lymphomas.
  • RESULTS: Out of the 385 cases that were diagnosed as lymphoma, 277 had non-Hodgkin's and 108 had Hodgkin's lymphomas.
  • Sixty-four point five percent of those with non-Hodgkin's lymphoma had the B type disease; 7.5% had the T-type; and the remaining 28% had Hodgkin's lymphoma.
  • In the present study, most (48%) patients with Hodgkin's lymphoma had mixed cellularity whereas in western countries the most common type is reported to be nodular sclerosis (69.4%).
  • CONCLUSION: The comparison made between the findings of this study and those of western countries indicates that high-grade non-Hodgkin's lymphomas are more prevalent in Iran.
  • [MeSH-major] Hodgkin Disease / classification. Hodgkin Disease / pathology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Europe / epidemiology. Humans. Incidence. Infant. Iran / epidemiology. Middle Aged. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17604472.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


59. Mushtaq S, Akhtar N, Jamal S, Mamoon N, Khadim T, Sarfaraz T, Waqar A: Malignant lymphomas in Pakistan according to the WHO classification of lymphoid neoplasms. Asian Pac J Cancer Prev; 2008 Apr-Jun;9(2):229-32
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All the cases diagnosed as malignant lymphoma, during the year 2005, were retrieved from the institution based tumour registry record and classified according to WHO criteria depending on the immunohistochemical results of a panel of lymphoma markers.
  • The frequency of Hodgkin's lymphoma, Burkitt's lymphoma and lymphoblastic lymphoma were higher amongst the children, whereas follicular lymphomas, mantle cell lymphoma and CLL/SLL were more frequently reported in 5th, 6th and 7th decades.
  • Non Hodgkin's lymphoma was more (73%) frequent than Hodgkin's disease.
  • Mixed cellularity and nodular sclerosis were the main histological variants of Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Prognosis. World Health Organization. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18712964.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


60. Chen L, Kuriakose P, Hawley RC, Janakiraman N, Maeda K: Hematologic malignancies with primary retroperitoneal presentation: clinicopathologic study of 32 cases. Arch Pathol Lab Med; 2005 May;129(5):655-60
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial presentation of disease in this site (primary retroperitoneal lymphoma) is considered to be rare.
  • Tumor types included diffuse large B-cell lymphoma (n = 12); grade 1 follicular lymphoma (n = 4); grade 3 follicular lymphoma (n = 1); B chronic lymphocytic leukemia/small lymphocytic lymphoma (n = 2); multiple myeloma (n = 1); mixed-cellularity Hodgkin lymphoma (n = 1); nodular sclerosis Hodgkin lymphoma (n = 1); aggressive B-cell lymphoma (n = 4); low-grade B-cell lymphoma (n = 4); lymphoblastic lymphoma, null cell type (n = 1); and precursor B-lymphoblastic lymphoma/leukemia (n = 1).
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor. Biopsy, Needle. Combined Modality Therapy. Female. Flow Cytometry. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Retroperitoneal Space. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859638.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


61. O'Toole O, O'Hare A, Grogan L, Bolger C, Brett FM: 20 year old lady with a paraspinal mass. Brain Pathol; 2010 May;20(3):683-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient underwent emergency resection of the lesion and pathology revealed Hodgkin's Lymphoma (HL)-mixed cellularity type.
  • CNS-HL is extremely rare and may occur de novo or in association with systemic disease.
  • Lesions may be parenchymal or dural based and are usually intracranial with an increased risk of CNS involvement in HL-mixed-cellularity type as in our patient.
  • [MeSH-major] Cervical Vertebrae / pathology. Hodgkin Disease / pathology. Spinal Canal / pathology. Spinal Cord Neoplasms / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20522095.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


62. Nagi AH, Al-Menawy LA, Samiullah, Naveed IA, Sami W: A comparison of histological appearances of Hodgkin's disease in Pakistani and Saudi patients. J Ayub Med Coll Abbottabad; 2008 Jul-Sep;20(3):66-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of histological appearances of Hodgkin's disease in Pakistani and Saudi patients.
  • BACKGROUND: Hodgkin's disease (HD) is a relatively rare lymphoma that affects younger as well as older persons.
  • It is reported in the Western as well as Asian studies that HD is a rare disease in developing world.
  • The commonest subtype is nodular sclerosis in the west and mixed cellularity in the eastern and developing countries.
  • The present study compares eight years' data of HD as regard age, sex, site of anatomical presentation and subtypes according to WHO classification among Pakistani and Saudi patients.
  • METHODS: This retrospective comparative study included 211 cases of HD from various institutions of Lahore, Pakistan; and 78 cases retrieved from the data of King Abdul Aziz Hospital and Oncology Centre, Jeddah, Saudi Arabia.
  • RESULTS: The analysis of both data of HD showed lack of bimodal age pattern and was common among younger age.
  • Mixed cellularity HD (MCHD) was the commonest subtype among Pakistani patients whereas Nodular Sclerotic HD (NSHD) was more common among Saudis.
  • CONCLUSION: A comparison of the pattern of Pakistani and Saudi data of HD showed lack of bimodality in both.
  • Morphologically the MCHD and NSHD were the commonest subtypes in Pakistani & Saudi patients respectively.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Chi-Square Distribution. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Retrospective Studies. Saudi Arabia / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19610520.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


63. Chakrabarti S, Sarkar S, Goswami BK, Mondal S, Roy A, Das S: Hodgkin's and Non-Hodgkin's lymphomas in an indian rural medical institution: comparative clinicopathologic analysis. Asian Pac J Cancer Prev; 2010;11(6):1605-8
MedlinePlus Health Information. consumer health - Lymphatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's and Non-Hodgkin's lymphomas in an indian rural medical institution: comparative clinicopathologic analysis.
  • In this prospective, hospital-based two year study, we comparatively evaluated clinicopathologic features of Hodgkin's lymphoma (HL, n = 48) and Non-Hodgkin's lymphoma (NHL, n = 76) in an Indian rural medical institution.
  • The commonest histological subtype was mixed cellularity (45.8%) in HL and diffuse mixed variant (31.6%) in NHL.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphatic Diseases. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Hospitals. Humans. Infant. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Rural Population. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21338204.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


64. Ramos Linares S, Breña Atienza J, Cháfer Rudilla M, Ríos Rull P, Cabello Rodríguez A, Merino Alonso J: Severe ifosfamide-induced neurotoxicity: a case report. Pharm World Sci; 2010 Apr;32(2):109-11
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE DESCRIPTION: We describe the case of a male with a mixed cellularity subtype classical Hodgkin's lymphoma, treated with ifosfamide after other chemotherapy drugs failure.
  • [MeSH-minor] Adult. Hodgkin Disease / drug therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033290.001).
  • [ISSN] 1573-739X
  • [Journal-full-title] Pharmacy world & science : PWS
  • [ISO-abbreviation] Pharm World Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


65. Bang SM, Cheong JW, Yang WI, Hahn JS: An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complications. Yonsei Med J; 2005 Jun 30;46(3):425-30
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complications.
  • Advanced Hodgkin's disease is usually treated with six or more cycles of combination chemotherapy.
  • Spontaneous regression of the cancer is very rarely reported in patients with Hodgkin's disease.
  • We present an unusual case of a patient with Hodgkin's disease who experienced complete remission with a single cycle of chemotherapy, followed by pneumonia.
  • The case was a 36-year-old man diagnosed with stage IVB mixed cellularity Hodgkin's disease in November 2000.
  • This report is followed by a short review of the literature on spontaneous regression of Hodgkin's disease.
  • To the best of our knowledge, this is the first case report of spontaneous remission of Hodgkin's disease in Korea.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Hodgkin Disease / complications. Hodgkin Disease / drug therapy. Pneumonia / complications. Prednisone / administration & dosage. Procarbazine / administration & dosage. Vinblastine / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Humans. Male. Remission, Spontaneous

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):145-55 [12621474.001]
  • [Cites] Am J Hematol. 2003 Feb;72(2):153-4 [12555225.001]
  • [Cites] Leuk Lymphoma. 2004 Jan;45(1):171-4 [15061215.001]
  • [Cites] Yonsei Med J. 2004 Jun 30;45(3):527-32 [15227742.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1189-201 [5329907.001]
  • [Cites] Lancet. 1970 May 16;1(7655):1016-20 [4191629.001]
  • [Cites] Lancet. 1971 Mar 20;1(7699):593 [4100922.001]
  • [Cites] Cancer. 1980 May 15;45(10):2627-32 [7378996.001]
  • [Cites] Br Med J. 1980 Mar 29;280(6218):903 [7388364.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):2093-9 [7427915.001]
  • [Cites] Lancet. 1981 May 16;1(8229):1112 [6112483.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] Cancer. 1988 Aug 15;62(4):791-4 [3395960.001]
  • [Cites] Am J Hematol. 1989 Jun;31(2):138-41 [2660545.001]
  • [Cites] Eur J Cancer. 1990;26(5):641-4 [2144756.001]
  • [Cites] Acta Oncol. 1990;29(5):545-50 [2206563.001]
  • [Cites] CA Cancer J Clin. 1993 Nov-Dec;43(6):327-46 [8242436.001]
  • [Cites] Cancer. 1994 Dec 1;74(11):3023-8 [7954265.001]
  • [Cites] J Clin Immunol. 1996 Nov;16(6):334-9 [8946278.001]
  • [Cites] Cancer Treat Rev. 1996 Nov;22(6):395-423 [9134002.001]
  • [Cites] Cancer Res. 1946 Apr;6:205-16 [21018724.001]
  • [Cites] Hematology. 2003 Jun;8(3):191-6 [12745644.001]
  • (PMID = 15988816.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CVPPABO protocol
  • [Number-of-references] 22
  • [Other-IDs] NLM/ PMC2815821
  •  go-up   go-down


66. Choi JH, Ahn MJ, Oh YH, Han SW, Kim HJ, Lee YY, Kim IS: Epstein-Barr virus-associated Hodgkin's disease following renal transplantation. Korean J Intern Med; 2006 Mar;21(1):46-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated Hodgkin's disease following renal transplantation.
  • The majority of the monomorphic PTLD cases are non-Hodgkin's lymphoma of B-cell origin.
  • Hodgkin's disease is not part of the typical spectrum of PTLD; however, it has been rarely reported.
  • We describe a case of Hodgkin's disease following renal transplantation.
  • A lymph node biopsy revealed mixed cellularity Hodgkin's disease.
  • No other site of disease was identified.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human. Hodgkin Disease / etiology. Immunosuppressive Agents / adverse effects. Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / chemically induced
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Ren Replace Ther. 2000 Apr;7(2):147-56 [10782732.001]
  • [Cites] Transplantation. 1997 Sep 27;64(6):848-52 [9326409.001]
  • [Cites] Transplant Proc. 2002 Jun;34(4):1178-81 [12072308.001]
  • [Cites] Pediatr Transplant. 2002 Dec;6(6):456-64 [12453197.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]
  • [Cites] Transplant Proc. 2003 Aug;35(5):1709-13 [12962767.001]
  • [Cites] Pediatr Transplant. 2004 Feb;8(1):87-90 [15009846.001]
  • [Cites] Pediatr Nephrol. 2004 Apr;19(4):369-77 [14986084.001]
  • [Cites] Blood. 1994 May 1;83(9):2715-22 [8167350.001]
  • [Cites] Semin Respir Infect. 1993 Sep;8(3):233-9 [8016484.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1005-19 [8049419.001]
  • [Cites] Transplant Proc. 1995 Apr;27(2):1783-4 [7725503.001]
  • [Cites] Dev Biol Stand. 1995;84:171-7 [7796951.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3333-40 [7579436.001]
  • [Cites] Transplantation. 1996 Jan 15;61(1):71-6 [8560577.001]
  • [Cites] Ann Oncol. 1996 Mar;7(3):265-70 [8740790.001]
  • [Cites] J Pediatr Hematol Oncol. 1996 Nov;18(4):392-5 [8888750.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1065-8 [11374404.001]
  • (PMID = 16646565.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ PMC3891064
  •  go-up   go-down






Advertisement